A Phase II Study of Sunitinib and Temsirolimus in Patients with Rare Tumours.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2018
At a glance
- Drugs Sunitinib (Primary) ; Temsirolimus (Primary)
- Indications Endometrial cancer; Haemangioblastoma; Haemangiosarcoma; Liver cancer; Malignant thymoma; Meningioma; Ovarian cancer; Paraganglioma; Phaeochromocytoma; Thyroid cancer
- Focus Therapeutic Use
- 21 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 11 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Dec 2017.
- 03 Feb 2016 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.